Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Breast 3Dermatologic 2Other neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Precancerous Conditions 1Melanoma 1

Interventions

Cyclophosphamide 7fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 6Whole-Body Irradiation 5Tacrolimus 4Mycophenolic Acid 4Methotrexate 4Melphalan 4Busulfan 4Sulindac 3Paclitaxel 3Cyclosporine 3Cisplatin 3Capecitabine 3Biopsy 3Antilymphocyte Serum 3toripalimab 2sintilimab 2fludarabine 2Taxes 2Surveys and Questionnaires 2Specimen Handling 2Sirolimus 2Radiotherapy 2Patient Reported Outcome Measures 2Nivolumab 2Mesna 2Magnetic Resonance Spectroscopy 2Hyperthermic Intraperitoneal Chemotherapy 2Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lovastatin × Other neoplasm × Clear all
NCT00462280 2014-10-31

Lovastatin in Treating Patients At High Risk of Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
80 enrolled 35 charts
DermatologicOther neoplasm

Melanoma, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡